Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a Healthcare company (Biotechnology) with a market capitalization of $6.1B. The Maz Rating grades it against the other companies in its sector.
Arrowhead Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $42.99, Arrowhead Pharmaceuticals, Inc. trades at 13.9x sales and 124.5x book value. Over the last twelve months it generated about $438M of revenue and a net loss of $700M. It runs a gross margin of 99.6%, an operating margin of -156.9% and a net margin of -160.6%. It shows return on equity of -170.6%, return on invested capital of -47.6% and a free cash flow yield of -4.5%. On the balance sheet: a debt-to-equity ratio of 19.88 and a current ratio of 4.14. Over the past 52 weeks the share price ranged from $37.06 to $95.49, with a beta of 1.37.
Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 16 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.06% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.4% / 30% · Interest income / Revenue 38.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 9.06% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.3% / 33% · Receivables / Mkt Cap (36m) 0.10% / 49% · Interest income / Revenue 38.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 9.06% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.3% / 33.33% · Receivables / Mkt Cap (24m) 0.10% / 33.33% · Interest income / Revenue 38.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 41.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 71.2% / 33.33% · Receivables / Avg Assets (4Q) 3.28% / 33.33% · Interest income / Revenue 38.0% / 5% | Fail |
| FTSE | Debt / Total Assets 50.6% / 33.33% · (Cash+ST Inv) / Total Assets 68.6% / 33.33% · (Cash+Recv) / Total Assets 69.2% / 33.33% · Interest income / Revenue 38.0% / 5% | Fail |
No. As of September 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Arrowhead Pharmaceuticals, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 38.0% of each dividend: Arrowhead Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q4 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.